                         SEQUENCE LISTING

<110>  EPIZYME, INC.
 
<120>  METHODS OF TREATING WHSC1-OVEREXPRESSING CANCERS

<130>  3562.018PC04

<150>  PCT/US2019/046569
<151>  2019-08-14

<150>  US 62/886,880
<151>  2019-08-14

<150>  US 62/857,120
<151>  2019-06-04

<150>  US 62/773,770
<151>  2018-11-30

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  19
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  SETD2 inhibitor

<400>  1
uaaaggaggu auaucgaau                                                    19


<210>  2
<211>  19
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  SETD2 inhibitor

<400>  2
gagagguacu cgaucauaa                                                    19


<210>  3
<211>  19
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  SETD2 inhibitor

<400>  3
gcucagaguu aacguuuga                                                    19


<210>  4
<211>  19
<212>  RNA
<213>  Artificial Sequence

<220>
<223>  SETD2 inhibitor

<400>  4
ccaaagauuc agacauaua                                                    19


<210>  5
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SETD2 inhibitor

<400>  5
cccattcact gtccacttga                                                   20


<210>  6
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  SETD2 inhibitor

<400>  6
ccctcaagtg gacagtgaat                                                   20


<210>  7
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  sgRNA Target Sequence #1

<400>  7
agcaccagta acagagccag                                                   20


<210>  8
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  sgRNA Target Sequence #2

<400>  8
gactgtgaac ggacaactga                                                   20


